pharmaglobenews

The pain management devices market is projected to witness significant growth from 2025 to 2032, driven by the rising prevalence of chronic pain, ongoing product innovations, and heightened awareness of treatment options. Increasing demand for minimally invasive solutions, alongside the influence of

The diffuse large B-cell lymphoma (DLBCL) market was valued at USD 4.7 billion across the leading markets (the US, EU4, UK, and Japan) in 2024. In the United States, the market is projected to exceed USD 11.5 billion by 2034, driven by

The demand for digital biomarkers is rising rapidly, driven primarily by the global increase in chronic diseases, including cardiovascular, neurological, and metabolic disorders. This growth is further supported by the expanding elderly population, which is more vulnerable to age-related health conditions. Additionally,

The cataract surgery complications market is projected to grow steadily from 2025 to 2034, driven by the introduction of new treatments, advancements in diagnostic technologies, increased awareness of the condition, and a growing number of reported cases, creating a dynamic and promising

DelveInsight’s “Mydriasis Market Insights, Epidemiology, and Market Forecast-2034” report delivers a comprehensive analysis of the Mydriasis market, covering historical and projected epidemiology, market trends, and developments across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. This report

According to DelveInsight’s analysis, the growth of the Cataract Surgery Devices Market is primarily driven by the rising prevalence of cataracts and vision impairment, increased incidence of lifestyle-related conditions contributing to cataract development, the expanding geriatric population, and accelerated product development initiatives

Marginal Zone Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys, Beijing Mabworks Biotech (Las Vegas, Nevada, United States) As per DelveInsight’s evaluation, globally, the Marginal Zone Lymphoma (MZL)

As per DelveInsight’s latest evaluation, the global Clostridium Difficile Infections therapeutic pipeline includes 20+ active companies involved in advancing 22+ CDI treatment candidates, covering clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and key ongoing developments. The “Clostridium Difficile Infections